Search Results - "DREAZEN, O"

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis by REITER-OWONA, I, PETERSEN, E, HAYDE, M, HOLLIMAN, R, HO-YEN, D. O, JANITSCHKE, K, JENUM, P. A, NASER, K, OLSZEWSKI, M, THULLIEZ, P, SEITZ, H. M, JOYNSON, D, ASPÖCK, H, DARDE, M. L, DISKO, R, DREAZEN, O, DUMON, H, GRILLO, R, GROSS, U

    Published in Bulletin of the World Health Organization (01-01-1999)
    “…The dye test for the detection of Toxoplasma-specific antibodies was first described by Sabin and Feldman 50 years ago. The test is highly specific and…”
    Get full text
    Journal Article
  2. 2

    A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia by Fainstein, E, Marcelle, C, Rosner, A, Canaani, E, Gale, R. P, Dreazen, O, Smith, S. D, Croce, C. M

    Published in Nature (London) (26-11-1987)
    “…The leukaemic cells of more than 90% of chronic myelogenous leukaemia (CML) patients and of 10% of acute lymphocytic leukaemia (ALL) patients carry the t(9:22)…”
    Get full text
    Journal Article
  3. 3

    Activation of the c-mos Oncogene in a Mouse Plasmacytoma by Insertion of an Endogenous Intracisternal A-Particle Genome by Canaani, E., Dreazen, O., Klar, A., Rechavi, G., Ram, D., Cohen, J. B., Givol, D.

    “…The activation of the cellular oncogene c-mos in mouse plasmacytoma XRPC24 was found to result from the insertion of a 4.7-kilobase-pair cellular DNA element,…”
    Get full text
    Journal Article
  4. 4

    bcr-abl RNA in Patients With Chronic Myelogenous Leukemia by Shtivelman, E., Gale, R.P., Dreazen, O., Berrebi, A., Zaizov, R., Kubonishi, I., Miyoshi, I., Canaani, E.

    Published in Blood (01-03-1987)
    “…The major consequence of the formation of the Philadelphia (Ph1) chromosome characteristic of leukemia cells of patients with chronic myelogenous leukemia…”
    Get full text
    Journal Article
  5. 5

    bcr-abl RNA in patients with chronic myelogenous leukemia by Shtivelman, E, Gale, RP, Dreazen, O, Berrebi, A, Zaizov, R, Kubonishi, I, Miyoshi, I, Canaani, E

    Published in Blood (01-03-1987)
    “…The major consequence of the formation of the Philadelphia (Ph1) chromosome characteristic of leukemia cells of patients with chronic myelogenous leukemia…”
    Get full text
    Journal Article
  6. 6

    Molecular Abnormalities of bcr and c-abl in Chronic Myelogenous Leukemia Associated With a Long Chronic Phase by Dreazen, Orna, Berman, Michael, Gale, Robert Peter

    Published in Blood (01-03-1988)
    “…Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years; <20% of patients have a chronic phase >7 years. It is unknown whether…”
    Get full text
    Journal Article
  7. 7

    Characterization of bcr gene products in hematopoietic cells by Li, W J, Dreazen, O, Kloetzer, W, Gale, R P, Arlinghaus, R B

    Published in Oncogene (01-02-1989)
    “…The bcr gene plays a critical role in the pathogenesis of two human leukemias associated with the Philadelphia chromosome: chronic myelogenous leukemia (CML)…”
    Get more information
    Journal Article
  8. 8

    CML-T1: A Cell Line Derived From T-Lymphocyte Acute Phase of Chronic Myelogenous Leukemia by Kuriyama, Kazutaka, Gale, Robert Peter, Tomonaga, Masao, Ikeda, Shuichi, Yao, Eiichi, Klisak, Ivana, Whelan, Kathy, Yakir, Hadas, Ichimaru, Michito, Sparkes, Robert S., Dreazen, Orna

    Published in Blood (01-09-1989)
    “…Most data suggest that malignant transformation in chronic myelogenous leukemia (CML) occurs in hematopoietic stem cell that is the progenitor of myelopoiesis…”
    Get full text
    Journal Article
  9. 9

    Accreditation of sampling activities by DREAZEN, Orna

    Published in Accreditation and quality assurance (01-06-2004)
    “…Since the introduction of ISO/IEC 17025 it is a requirement for all accredited laboratories to include sampling in their quality statements. It is well…”
    Get full text
    Conference Proceeding Journal Article
  10. 10

    B cell acute lymphoblastic leukemia (ALL) in donor cells following bone marrow transplantation for T cell ALL by Feig, S A, Dreazen, O, Simon, M, Wiley, F, Schreck, R, Gale, R P

    Published in Bone marrow transplantation (Basingstoke) (01-07-1988)
    “…Leukemia recurred in a child with acute lymphoblastic leukemia after a bone marrow transplant. The pre-transplant leukemia was of T cell origin whereas the…”
    Get more information
    Journal Article
  11. 11

    Current best practice for traceability in testing laboratories, when certified reference materials are unavailable by ENGELHARD, Tina, DREAZEN, Orna

    Published in Accreditation and quality assurance (01-06-2004)
    “…Since the implementation of ISO/IEC 17025 in 2002, all accredited laboratories (at the least) need to establish traceability in all their tests and calibration…”
    Get full text
    Conference Proceeding Journal Article
  12. 12

    Proficiency testing as a tool for assessing the medical and economic impact of laboratory results: The blood coagulation case by DREAZEN, Orna, FELLER, Etty, LESHNO, Moshe

    Published in Accreditation and quality assurance (01-06-2003)
    “…An international commercial proficiency testing scheme was used to evaluate the impact of laboratory results on clinical decisions. The affect on atrial…”
    Get full text
    Conference Proceeding Journal Article
  13. 13

    Influence of buffer quality on pH measurement uncertainty: prediction and experimental evaluation by Ekeltchik, Irina, Kardash-Strochkova, Elena, Dreazen, Orna, Kuselman, I.

    Published in Accreditation and quality assurance (01-10-2002)
    “…Dependence of the uncertainty of a pH measurement result on the quality of buffers (i.e. the uncertainty of their certified pH values) at different levels of…”
    Get full text
    Journal Article
  14. 14

    Do oncogenes determine clinical features in chronic myeloid leukaemia? by Dreazen, O, Klisak, I, Rassool, F, Goldman, J M, Sparkes, R S, Gale, R P

    Published in The Lancet (British edition) (20-06-1987)
    “…Oncogene abnormalities are thought to have a central role in some human malignant disorders, particularly Burkitt leukaemia/lymphoma and chronic myeloid…”
    Get more information
    Journal Article
  15. 15

    Molecular biology of chronic myelogenous leukemia by Dreazen, O, Canaani, E, Gale, R P

    Published in Seminars in hematology (01-01-1988)
    “…In this review we have described molecular consequences of the t(9;22) translocation typical of CML and some cases of ALL. This data indicates an important…”
    Get more information
    Journal Article
  16. 16

    Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase by Dreazen, O, Berman, M, Gale, RP

    Published in Blood (01-03-1988)
    “…Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years; less than 20% of patients have a chronic phase greater than 7 years. It…”
    Get full text
    Journal Article
  17. 17

    Multiple molecular abnormalities in Ph1 chromosome positive acute lymphoblastic leukaemia by Dreazen, O, Klisak, I, Jones, G, Ho, W G, Sparkes, R S, Gale, R P

    Published in British journal of haematology (01-11-1987)
    “…The Ph1 chromosome is present in 95% of patients with chronic myelogenous leukaemia (CML). The Ph1 chromosome also occurs in 5-25% of children and adults with…”
    Get more information
    Journal Article
  18. 18

    The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia by Dreazen, O, Klisak, I, Rassool, F, Goldman, J M, Sparkes, R S, Gale, R P

    Published in Oncogene research (1988)
    “…The relationship between chronic myelogenous leukemia (CML) with and without the Ph1 chromosome is controversial. Although some suggest that these disorders…”
    Get more information
    Journal Article
  19. 19

    A Ph1 chromosome positive B cell line expresses the fusion protein P 210 by Munker, R, Miller, C W, Berenson, J, Dreazen, O, Koeffler, H P

    “…We established a B lymphocyte line from bone marrow cultures of a patient with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia. The cell…”
    Get more information
    Journal Article
  20. 20

    The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region by Rassool, F, Foroni, L, Rahemtulla, A, Dreazen, O, Wiedemann, L, Guo, A P, Legon, S, Catovsky, D, Luzzatto, L, Goldman, J

    Published in Cancer genetics and cytogenetics (01-06-1988)
    “…We report a case of acute leukemia in which studies at presentation showed both myeloid and lymphoid cell surface markers. At relapse membrane markers studies…”
    Get more information
    Journal Article